Agilent Technologies reports that it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market. The new Train C and D manufacturing lines will be based in Agilent’s Frederick, Colorado facility, where a Train B manufacturing line, announced in 2020, will go live later this year. Source: Genetic Engineering News 10/1/2023